OTC Stock News

[budfoxfun]

$EMED's Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

[budfoxfun]

$EMED The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

[Robertscott]

$EMED
The WellnessPro Plus®

triggers our body’s natural processes. Electrical impulses travel from nerves around the injured area to our brain, delivering the unpleasant sensation of pain. WellnessPro Plus® operates by disrupting these pain signals received by our synapses, mimicking our natural electric signals to relieve patients from pain.

Electromedical Technologies brought together some of the leading biomedical researchers from around the world to develop next generation TENS machines. Through product innovation and a forward-thinking approach, we succeeded to develop specific algorithms in electrotherapy that work to alleviate pain.

[Robertscott]

$EMED Electrotherapy seems to be one of the most promising substitute to toxic and addictive painkillers. Since introducing the WellnessPro+ in 2007, ElectroMedical Technologies has been an innovation pioneer at the forefront of the alternative pain relief movement.

[Let's Roll]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$EMED Bio-electrical stimulation is a safe non toxic pain management therapy that activates the body’s innate
ability to heal itself. Therapy provides targeted pain alleviation to specific areas of the body by
modifying its electrical language related to pain, regulating signals and stimulating endogenous opioids
distributed in the nervous systems, particularly in circuits involved in pain modulation, reward,
responses to stress, and autonomic control.

[budfoxfun]

$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.

https://electromedtech.com/electrotherapy-explained/

[Let's Roll]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[budfoxfun]

$EMED Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Company's Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

[budfoxfun]

$GMPR Now Selling Gluten-Free Pizzas in Buehler's Fresh Foods Grocery Stores https://finance.yahoo.com/news/gourmet-provisions-international-corp-gmpr-130000912.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[dunnvideo]

$SGTM is on various social media forums:

Facebook - https://www.facebook.com/TheSustainableGreenTeam
Twitter - https://twitter.com/TheSGTM
LinkedIn - https://www.linkedin.com/company/national-storm-recovery/mycompany
YouTube - https://www.youtube.com/channel/UCfHOXw680FaaIb_Qzj6IuLg
Vimeo - https://www.vimeo.com/sgtm

[Let's Roll]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$EMED as the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[Robertscott]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$EMED SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

[budfoxfun]

$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.

https://electromedtech.com/electrotherapy-explained/

[Let's Roll]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[Let's Roll]

$SGTM will host a virtual Annual Shareholder Meeting to discuss its 2022 fiscal year end results, including 2022 highlights, and its upcoming 2023 outlook at 9:00am Eastern Time. To participate in the meeting please RSVP by clicking here.

Tony Raynor, SGTM’s Chief Executive Officer commented, "I am very proud of our team. Without them we wouldn’t be able to continue to grow our company year over year. I look forward to our first Annual Shareholder Meeting to discuss all that we have achieved during 2022, our plans for 2023, and talking to our loyal shareholders.”

https://www.stocktitan.net/news/SGTM/the-sustainable-green-team-ltd-reports-35-5m-in-revenue-and-120-3m-ic515u2n4vyv.html

[Robertscott]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[budfoxfun]

$EMED pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

[budfoxfun]

$EMED preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED News: SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[Let's Roll]

$EMED University research centers, doctors, and physicians around the world have overseen treatments using electrotherapy with outstanding results in the reduction of pain for a wide range of acute and chronic conditions. The WellnessPro Plus is an effective complementary treatment modality for pain relief.

[Robertscott]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[Let's Roll]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[budfoxfun]

$EMED their preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

[Let's Roll]

$SGTM will host a virtual Annual Shareholder Meeting to discuss its 2022 fiscal year end results, including 2022 highlights, and its upcoming 2023 outlook at 9:00am Eastern Time. To participate in the meeting please RSVP by clicking here.

Tony Raynor, SGTM’s Chief Executive Officer commented, "I am very proud of our team. Without them we wouldn’t be able to continue to grow our company year over year. I look forward to our first Annual Shareholder Meeting to discuss all that we have achieved during 2022, our plans for 2023, and talking to our loyal shareholders.”

https://www.stocktitan.net/news/SGTM/the-sustainable-green-team-ltd-reports-35-5m-in-revenue-and-120-3m-ic515u2n4vyv.html

[Robertscott]

$EMED Electrotherapy is a nerve stimulation therapy via carefully developed electrical impulses mimicking our
body signals to help restore damages caused by injuries or accidents.
Significant percentage of patients found TENS devices effectively reduced their pain.

https://electromedtech.com/electrotherapy-explained/

[budfoxfun]

$USAU Alliance Global Partners’ analyst, Jake Sekelsky, put a $25.00 target on U.S. Gold Corp. (NASDAQ: USAU) https://www.tgd8hjs.com/4XKLCJ/4M1J6TW/ $INDP $SAND $AU $AEM $NIO $GLD $LEGN $LUNR $RGLD $FNV

[Robertscott]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[budfoxfun]

$EMED News: SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

[budfoxfun]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[Let's Roll]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[Let's Roll]

$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.

https://electromedtech.com/investors-relations/

[Let's Roll]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[budfoxfun]

$EMED During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

[Robertscott]

$EMED Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

[BjornTrader]

$ADHC promising tweet!

$adhc @ADHCMANAGEMENT @rollschoice https://t.co/oBLtydbtKh under complete overhaul, amazing CBD products under production, full scale launch coming !!!!!! pic.twitter.com/23Ascxk1hH

— ADHC MANAGEMENT $ADHC (@ADHCMANAGEMENT) April 17, 2023

[budfoxfun]

$EMED over a million frequencies to choose from, WellnessPro Plus® offers the widest frequency range on the market allowing it to have numerous applications. FDA CLEARED, it features a “future-ready” modular design, making it widely adaptable to new accessories and therapies.

[Let's Roll]

$EMED When it comes to electricity created in the human body, the energy source is chemical and has to do with the composition of the atoms and molecules present. All the elements we take into our bodies, such as oxygen, sodium, potassium, calcium, magnesium etc., have a specific electrical charge. How those molecules are bound together and how they react to other molecules near them is how chemicals create energy. Some of these electrical impulses found naturally in our bodies activate functions needed for healing.

[Robertscott]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.

[budfoxfun]

$EMED During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.

Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.

The WellnessPro Infinity™ sets a new standard in the bioelectronics and electrotherapy marketplace featuring support for all modalities:

Designed to support*: TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pulse™, cloud access and much more.

Unprecedented accuracy.

Easiest to use electrotherapy device on the market.

New Doctor-Patient Portal for updates and personalized treatments.

Wolfson concluded, "Last year was an ambitious year focused on key R&D objectives that we have met and now we are laying a strong foundation for handling business at a far larger scale. We accomplished everything we set out to accomplish and managed to log impressive sales growth along the way. We are also in the process of expanding consumer resources for purchasing Electromedical products. We have added FSA/HSA purchasing optionality already, and we have some more news coming that could sharply increase customer affordability without impacting our margins, and we look forward to discussing that in further detail very soon."

Management notes that 2023 will see the launch of the WellnessPro Infinity™, continued expansion in its sales team, a strong focus on value-add strategic partnerships, research partnerships and further customer affordability strategies as the Company monetizes its market-leading next-generation drug-free pain therapy technology.

The Company has approximately 10,000 past clients. We expect that we will be successful in encouraging a significant part of our past clients to exchange their old units for the improved Wellness Pro Infinity unit with lifetime warranty. Our development process is progressing and we look forward to providing more updates very soon. We will be in a position to start accepting advance deposits in Q2 for these units, which will greatly enhance the Company's cash position.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

For more information, please visit www.electromedtech.com

[budfoxfun]

$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.